Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in October 2013 on request of the sponsor.
On 17 July 2013, orphan designation (EU/3/13/1159) was granted by the European Commission to Gilead Sciences International Ltd, United Kingdom, for idelalisib for the treatment of follicular lymphoma.
For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.
|Disease / condition||
Treatment of follicular lymphoma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.